IMMX - Immix Biopharma, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.45 0.12 (4.96%)	---	---	---	0.03 (1.22%)	0.14 (5.65%)	0.0 (0.05%)	0.0 (0.05%)

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.22
Diluted EPS:: -0.22
Basic P/E:: -11.6882
Diluted P/E:: -11.6882
RSI(14) 1m:: 100.0
VWAP:: 2.57
RVol:: 1.2404

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	2.63 +0.03 (+1.18%)	Oct 15 15:51
1m	Price decrease 1m	2.5 -0.05 (-1.96%)	Oct 15 13:11
1m	Price decrease 1m	2.6 -0.03 (-1.14%)	Oct 15 12:06
1m	Price decrease 1m	2.62 -0.03 (-1.02%)	Oct 15 12:05
1m	Price decrease 1m	2.6 -0.03 (-1.29%)	Oct 15 10:10